Nkarta, Inc. (NKTX): Total Assets
$404.21M
As of 2025-12-31
$337.64M
As of 2026-06-30
-5.1%
3-year compound annual growth
+3.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $404.21M | -19.4% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $501.20M | +32.3% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $378.88M | -19.9% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $472.94M | +72.7% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $273.90M | -18.9% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $337.65M | +597.5% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $48.41M | n/a | 2021-03-25, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Nkarta, Inc. (NKTX) | 2025-12-31 | $404.21M | -19.4% |
| Abbott Laboratories (ABT) | 2025-12-31 | $86.71B | +6.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $90.04B | -2.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $112.48B | +42.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $208.16B | -2.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $199.21B | +10.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $261.15M | +8.4% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $136.87B | +16.9% |
Compare NKTX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗